BidaskClub upgraded shares of Verastem (NASDAQ:VSTM) from a hold rating to a buy rating in a research report report published on Monday.
A number of other equities analysts have also issued reports on the stock. Cann reiterated a buy rating and set a $13.00 target price on shares of Verastem in a research report on Friday, January 26th. B. Riley set a $15.00 target price on shares of Verastem and gave the stock a buy rating in a research report on Friday, March 23rd. Cantor Fitzgerald reiterated a buy rating and set a $17.00 target price on shares of Verastem in a research report on Wednesday, February 7th. Zacks Investment Research upgraded shares of Verastem from a hold rating to a buy rating and set a $3.75 target price on the stock in a research report on Saturday, March 17th. Finally, Seaport Global Securities started coverage on shares of Verastem in a research report on Wednesday, May 2nd. They set a buy rating and a $14.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Verastem presently has an average rating of Buy and a consensus target price of $11.25.
Get Verastem alerts:
Shares of Verastem opened at $5.15 on Monday, MarketBeat.com reports. Verastem has a 1 year low of $4.99 and a 1 year high of $5.24. The company has a market cap of $279.10 million, a PE ratio of -2.93 and a beta of 2.18. The company has a current ratio of 4.45, a quick ratio of 4.45 and a debt-to-equity ratio of 0.39.
Verastem (NASDAQ:VSTM) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.02). research analysts predict that Verastem will post -1.47 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in VSTM. BVF Inc. IL acquired a new position in Verastem in the fourth quarter valued at approximately $6,908,000. AWM Investment Company Inc. acquired a new position in Verastem in the fourth quarter valued at approximately $1,408,000. Monashee Investment Management LLC acquired a new position in Verastem in the fourth quarter valued at approximately $844,000. Victory Capital Management Inc. acquired a new position in Verastem in the first quarter valued at approximately $816,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Verastem by 93.9% in the third quarter. Dimensional Fund Advisors LP now owns 561,969 shares of the biopharmaceutical company’s stock valued at $2,641,000 after buying an additional 272,141 shares during the period. Institutional investors and hedge funds own 30.19% of the company’s stock.
Verastem Company Profile
Verastem, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.